Sugammadex-induced anaphylactic shock

Article information

Anesth Pain Med. 2020;15(1):131-131
Publication date (electronic) : 2020 January 31
doi :
1Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2Department of Anesthesiology and Pain Medicine, Daejeon Sun Medical Center, Daejeon, Korea
Corresponding author: Hong Seuk Yang, M.D., Ph.D. Department of Anesthesiology and Pain Medicine, Daejeon Sun Medical Center, 29 Mokjung-ro, Jung-gu, Daejeon 34811, Korea Tel: 82-42-220-8921 Fax: 82-42-220-8933 E-mail:
Received 2019 September 10; Accepted 2019 December 2.

Since sugammadex has begun to be clinically used as an antagonist of nondepolarizing neuromuscular blockers, there have been many reports of its side effects, such as anaphylaxis. We read with great interest the paper titled “A suspected sugammadex-induced anaphylactic shock-A case report.” We have some concerns, which we want to discuss.

Transthoracic echocardiography was considered effective for the diagnosis and treatment in this case. Impairment of the coronary circulation can occur in cases of anaphylaxis [1,2]. In this case, rocuronium was continuously infused during anesthesia. However, the depth of the neuromuscular blockade during the operation should have been mentioned. Among the reports on maintenance of the neuromuscular blockade during surgery, some papers suggest that profound neuromuscular blockade is effective but that it is better to maintain 95–97% neuromuscular blockade [3,4]. Further, the depth of the neuromuscular blockade at the time of injecting 200 mg of sugammadex should have been mentioned. In addition, 200 mg of sugammadex was administered at a dose of 3.257 mg/kg in this patient, who weighed 61.4 kg. However, a basis of determining this dose should have been provided. Furthermore, it remains unclear whether or not this dose was sufficient [3,4].

Identification of the antigen is considered an important component of patient care. Three suspicious substances, including rocuronium, sugammadex, and the rocuronium–sugammadex complex, should be selected as antigens for the skin test in cases of anaphylaxis following the administration of rocuronium and sugammadex. It will be helpful to identify the causative substances of anaphylaxis [5].



No potential conflict of interest relevant to this article was reported.


Kounis NG. 2013;Coronary hypersensitivity disorder: the Kounis syndrome. Clin Ther 35:563–71. 10.1016/j.clinthera.2013.02.022. 23490289.
Kounis NG. 2016;Kounis syndrome: an update on epidemiology, pathogenesis, diagnosis and therapeutic management. Clin Chem Lab Med 54:1545–59. 10.1515/cclm-2016-0010. 26966931.
Lien CA, Kopman AF. 2014;Current recommendations for monitoring depth of neuromuscular blockade. Curr Opin Anaesthesiol 27:616–22. 10.1097/ACO.0000000000000132. 25251919.
Brull SJ, Kopman AF. 2017;Current status of neuromuscular reversal and monitoring: challenges and opportunities. Anesthesiology 126:173–90. 10.1097/ALN.0000000000001409. 27820709.
Baldo BA. 2019;Anaphylaxis caused by sugammadex- rocuronium inclusion complex: what is the basis of the allergenic recognition? J Clin Anesth 54:48–9. 10.1016/j.jclinane.2018.10.017. 30391455.

Article information Continued